Researchers at Washington University in St. Louis have a unique resource in the form of the Center for Biomolecular ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer ...

Function Health, a startup that offers lab testing and body scans for early disease detection, scored nearly $300 million in series B funding, boosting its valuation to $2.5 billion. Redpoint Ventures ...

Never one to shy away from technology, Lyndsay Munro embraced the rise of generative artificial intelligence with the same enthusiasm she brings to her lecture halls. She soon turned the fast-evolving ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. It is an exciting time for researchers working to link proteins to their functions.

Function Health said it acquired full-body MRI scanning company Ezra. Function offers a $499 annual subscription where members complete more than 160 blood tests and track their results over time.

Pegbelfermin shows significant improvements in liver fibrosis markers, adiponectin, and PRO-C3 concentrations in MASH patients compared to placebo. Liver stiffness and NASH CRN Fibrosis Score did not ...

Stimulating the body’s immune defenses against a tumor can reduce or eliminate it. However, in cancer immunotherapy, when immune checkpoint inhibitors unleash the immune system, severe autoimmunity ...

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. Glutamine synthetase (GS) is an ancient enzyme present in all ...

Elite road cyclists are becoming chemistry experts. Lightweighting their equipment with sophisticated materials such as carbon nanofibers has helped ease these athletes over many hills. They’ve ...

ABSTRACT: The authors aimed to prove that an increase in high-sensitivity Troponin (hsTnT) levels correlates with the corrected QT (QTc) interval measured during a standard 12-lead ECG. From the ...

VIENNA — Treatment with a novel lysophosphatidic acid receptor 1 (LPA1) antagonist was associated with significant changes in baseline biomarkers of disease in adults with pulmonary fibrosis, based on ...